Interview with Ellen Velisek, RN, BSN, OCN: Preparing Patients for CAR T-Cell Therapy

The Evolving Field of CAR T-Cell Therapy

Interview with Joseph "Burl" and Judy Webnar: The Patient/Caregiver Experience of Receiving CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

CAR T-Cell Therapy Resource Center

Interview with Ellen Velisek, RN, BSN, OCN: Preparing Patients for CAR T-Cell Therapy

Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Leukemia and Lymphoma Society: CAR T-Cell Therapy

ASTCT 2022 National Fludarabine Shortage for HCT and CAR T-Cell Recipients: Frequently Asked Questions

Lymphoma Research Foundation: Treatment Options: CAR T-Cell Therapy

American Cancer Society: CAR T-Cell Therapy and its Side Effects

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Translational Oncology

Development and characterization of anti-CXCR4 chimeric antigen receptor T cells

Blood

How I Treat HLH-Like Toxicities Following Immune Effector Cell Therapy

Blood Advances

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review

Journal of Medical Economics

Time to access matters: Patient gains from faster CAR T-cell reimbursement in Europe

British Journal of Clinical Pharmacology

Efficacy, safety and cost-effectiveness of CAR-T therapy

Immunology

Strategies of AI-driven CAR-T cell therapy towards solid tumours

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Fast Facts #12: BCMA Targets